HighGravityDataCurrent guidance
4 items
Zimmer Biomet
Guidance from Zimmer Biomet’s last 8 earnings releases. Every value links to its sentence in the filing. See something wrong? Tell us.
Releases tracked
8
Latest release
Aug 5, 2026
Data checked
Aug 5, 2026
What changed in the Aug 5, 2026 release
Each item compared with the same item in the previous release (Apr 28, 2026). Values in quotation marks are the company’s words.
New — first stated in this releaseRaised / Lowered / Narrowed / Widened — changed from the prior releaseRevised — wording changed, direction not determinableChanged — value changed; the comparison couldn’t be parsed to a directionReiterated — restated unchangedNot restated — stated before, absent nowRaised and lowered describe the number, not whether the change is favorable.
| Change | Metric | Period | Previous | Now | Source |
|---|---|---|---|---|---|
| Raised | Constant Currency Revenue Change | for FY2026 | “2.0% - 4.0%” | “3.4% - 4.4%” | Filing ↗ |
| Raised | Organic Constant Currency Revenue Change (1) | for FY2026 | “1.0% - 3.0%” | “2.25% - 3.25%” | Filing ↗ |
| Raised | Adjusted Diluted EPS (2) | for FY2026 | “$8.40 - $8.55” | “$8.47 - $8.59” | Filing ↗ |
| Reiterated | Foreign Currency Exchange Impact | for FY2026 | “+0.5%” | “+0.5%” | Filing ↗ |
Current guidance
Guidance for periods that have not yet ended, at its most recent value, grouped by horizon.
Current fiscal year
| Metric | Current value | Period | Measure | First stated | Times stated | Source |
|---|---|---|---|---|---|---|
| Constant Currency Revenue Change | “3.4% - 4.4%” | for FY2026 | Company-defined | Feb 10, 2026 | 3 | Filing ↗ |
| Organic Constant Currency Revenue Change (1) | “2.25% - 3.25%” | for FY2026 | Company-defined | Feb 10, 2026 | 3 | Filing ↗ |
| Adjusted Diluted EPS (2) | “$8.47 - $8.59” | for FY2026 | Company-defined | Feb 10, 2026 | 3 | Filing ↗ |
| Foreign Currency Exchange Impact | “+0.5%” | for FY2026 | Company-defined | Feb 10, 2026 | 3 | Filing ↗ |
| Share repurchase expectations | “up to $1 billion of its common stock” | for FY2026 | Declared action | Aug 5, 2026 | 1 | Filing ↗ |
No period stated
| Metric | Current value | Period | Measure | First stated | Times stated | Source |
|---|---|---|---|---|---|---|
| Stock repurchase authorization | “up to $1.5 billion in common stock” | — | Declared action | Feb 10, 2026 | 1 | Filing ↗ |
How one item moved
Foreign Currency Exchange Impact, for FY2025 — every statement across the year, each linked to its filing.
How your Medical devices & equipment sector group guides
12 companies in Medical devices & equipment. What they guide on, and who reported this season.
Most-guided metric families
This season’s releases
| Medtronic | Sep 1, 2026 | 3 changes |
| Becton Dickinson | Aug 6, 2026 | 4 changes |
| ResMed | Aug 6, 2026 | 0 changes |
| Insulet | Aug 5, 2026 | 25 changes |
| Zimmer Biomet | Aug 5, 2026 | 3 changes |
| DexCom | Jul 30, 2026 | 3 changes |
| Stryker | Jul 30, 2026 | 2 changes |
| Boston Scientific | Jul 29, 2026 | 5 changes |
Get this for your own peer set — Peer Guidance Briefing, $3,000.
Full history
Every metric, every release, eight quarters — the complete record as one table.
| Metric | FY2026 | FY2025 | FY2024 | No period |
|---|---|---|---|---|
| Constant Currency Revenue Change | 3 statements | 4 statements | 1 statement | — |
| Organic Constant Currency Revenue Change (1) | 3 statements | 3 statements | — | — |
| Reported revenue growth | — | 1 statement | — | — |
| Adjusted Diluted EPS (2) | 3 statements | 4 statements | 1 statement | — |
| Adjusted earnings per share financial | — | 1 statement | — | — |
The full record for Zimmer Biomet and its Medical devices & equipment peers, delivered as a Peer Guidance Briefing — PDF and Excel, every value linked to its filing.
Filings
The 8 earnings releases this page is built from.
| Filed | Fiscal period | Accession | Guidance items | |
|---|---|---|---|---|
| Aug 5, 2026 | FY2026 Q2 | 0001193125-26-333761 | 5 | Open filing ↗ |
| Apr 28, 2026 | FY2026 Q1 | 0001193125-26-183411 | 4 | Open filing ↗ |
| Feb 10, 2026 | FY2025 Q4 | 0001193125-26-043620 | 5 | Open filing ↗ |
| Nov 5, 2025 | FY2025 Q3 | 0001193125-25-265649 | 4 | Open filing ↗ |
| Aug 7, 2025 | FY2025 Q2 | 0000950170-25-104527 | 6 | Open filing ↗ |
| May 5, 2025 | FY2025 Q1 | 0000950170-25-063124 | 4 | Open filing ↗ |
| Feb 6, 2025 | FY2024 Q4 | 0000950170-25-014972 | 3 | Open filing ↗ |
| Oct 30, 2024 | FY2024 Q3 | 0000950170-24-118573 | 3 | Open filing ↗ |
Values in quotation marks are the company’s words; the classification and filing links are HighGravityData’s. HighGravityData does not score or rank companies or give investment advice.
Report an error